PIK3CA and prostate carcinoma: For instance, blocking the PI3K/AKT axis in prostate cancer cells by the administration of the PI3K inhibitor ZSTK474 prevents bone metastasis in vivo via downregulation of the pro-invasive MMP9 [136].